Skip to content
Macrilen, Ghryvelin (previously macimorelin aeterna zentaris)(macimorelin)
Ghryvelin, Macrilen (macimorelin) is a small molecule pharmaceutical. Macimorelin was first approved as Macrilen on 2017-12-20. It has been approved in Europe to treat endocrine diagnostic techniques. The pharmaceutical is active against growth hormone secretagogue receptor type 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
diagnosisD003933
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Macimorelin acetate
Tradename
Company
Number
Date
Products
MACRILENKazia TherapeuticsN-205598 DISCN2017-12-20
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
macrilenNew Drug Application2019-11-27
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
MACIMORELIN ACETATE, MACRILEN, NOVO
2024-12-20ODE-170
Patent Expiration
Patent
Expires
Flag
FDA Information
Macimorelin Acetate, Macrilen, Novo
81927192027-10-12U-2220
ATC Codes
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CD: Pituitary function test diagnostic agents
— V04CD06: Macimorelin
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Laron syndromeD046150Orphanet_633E34.321——3——3
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMACIMORELIN
INNmacimorelin
Description
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate.
Classification
Small molecule
Drug classprehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O
Identifiers
PDB—
CAS-ID381231-18-1
RxCUI—
ChEMBL IDCHEMBL278623
ChEBI ID—
PubChem CID9804938
DrugBankDB13074
UNII ID8680B21W73 (ChemIDplus, GSRS)
Target
Agency Approved
GHSR
GHSR
Organism
Homo sapiens
Gene name
GHSR
Gene synonyms
NCBI Gene ID
2693
Protein name
growth hormone secretagogue receptor type 1
Protein synonyms
GH-releasing peptide receptor, Ghrelin receptor, GHRP, GHS-R
Uniprot ID
Q92847
Mouse ortholog
Ghsr (208188)
growth hormone secretagogue receptor type 1 (Q99P50)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Macrilen - Strongbridge Biopharma
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 100 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
316 adverse events reported
View more details